Calian Group (TSE:CGY) Price Target Raised to C$85.00

Calian Group (TSE:CGY) had its price objective lifted by Acumen Capital from C$70.00 to C$85.00 in a report released on Friday morning,BayStreet.CA reports. They currently have a buy rating on the stock.

CGY has been the topic of several other research reports. Royal Bank Of Canada boosted their target price on shares of Calian Group from C$58.00 to C$60.00 and gave the stock an “outperform” rating in a report on Friday. Ventum Financial lifted their price target on shares of Calian Group from C$62.00 to C$72.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Canaccord Genuity Group increased their price objective on shares of Calian Group from C$63.00 to C$80.00 in a report on Friday. Desjardins raised their price objective on Calian Group from C$59.00 to C$66.00 and gave the company a “buy” rating in a research report on Thursday, November 27th. Finally, Canadian Imperial Bank of Commerce lifted their target price on Calian Group from C$65.00 to C$76.00 in a report on Friday. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, Calian Group has a consensus rating of “Buy” and a consensus target price of C$74.83.

Calian Group Stock Performance

TSE:CGY opened at C$70.60 on Friday. The company has a current ratio of 1.29, a quick ratio of 1.20 and a debt-to-equity ratio of 39.54. Calian Group has a 12-month low of C$37.70 and a 12-month high of C$71.92. The stock has a 50-day moving average price of C$60.38 and a 200 day moving average price of C$54.15. The stock has a market capitalization of C$805.62 million, a P/E ratio of 30.96, a P/E/G ratio of 2.50 and a beta of 0.70.

Calian Group (TSE:CGY) last posted its quarterly earnings results on Thursday, February 12th. The company reported C$1.03 EPS for the quarter. Calian Group had a return on equity of 3.37% and a net margin of 1.50%.The company had revenue of C$208.00 million for the quarter. Equities research analysts forecast that Calian Group will post 4.9475219 EPS for the current fiscal year.

Calian Group Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 11th. Shareholders of record on Wednesday, March 11th will be paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date of this dividend is Wednesday, February 25th. Calian Group’s dividend payout ratio (DPR) is presently 49.12%.

More Calian Group News

Here are the key news stories impacting Calian Group this week:

• Positive Sentiment: Record Q1 results — Calian reported C$208M revenue (up ~12% YoY) with margin gains and C$1.03 EPS, and management signaled confident growth on the earnings call; this strengthens the growth narrative driving buying interest. Calian Delivers Record Q1 Revenue and Margin Gains
• Positive Sentiment: Multiple analyst target upgrades — Acumen (to C$85, Buy), Canaccord (to C$80), CIBC (to C$76) and Ventum (to C$82, Buy) raised price targets, signaling broad analyst optimism and providing upward catalyst for the stock. Analyst Ratings Roundup
• Positive Sentiment: Quarterly dividend declared — Board approved a C$0.28 quarterly dividend (annualized yield ~1.6%), with ex-dividend Feb 25 and record Mar 11; supports shareholder return profile and can attract income-minded buyers.
• Neutral Sentiment: Corporate governance update — Shareholders re‑elected the board and named Valerie Sorbie as Chair, which preserves leadership continuity but is unlikely to move the stock materially by itself. Shareholder Meeting Results
• Negative Sentiment: RBC’s moderate target bump to C$60 — Although RBC maintained an “outperform” stance, its target remains well below the current price, indicating at least one major analyst sees less upside and creating potential resistance or caution among some investors. RBC Target Update

Calian Group Company Profile

Calian Group Ltd operates through four segments namely Advanced Technologies, Health, Learning, and Information Technology. It generates maximum revenue from the Health segment. The company serves health, defence, security, aerospace, engineering, AgTech, and IT industries. Its Health segment includes Clinical Services; Nursing Services; Psychological Services and Medical Property Management. The Advanced Technologies segment includes Engineering Solutions and Services; Nuclear and Environmental Services; Satcom; DOCSIS; Electronics Design and Manufacturing and Agricultural Technology.